Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Low levels of high-density lipoprotein cholesterol (HDL-C) are a significant predictor of coronary artery disease (CAD).
• HDL's primary anti-atherogenic role is reverse cholesterol transport, dependent on apolipoprotein A-I (apoA-I) and apolipoprotein E (apoE).
• Current lipid-lowering drugs have limitations, including side effects and residual risk in CAD patients with low HDL-C.

Purpose of the Study:

• To review the therapeutic potential of synthetic apolipoprotein mimetic peptides for CAD.
• To discuss apoA-I mimetic peptides that have entered clinical trials.
• To explore novel apoE mimetics with lipid-clearing and anti-inflammatory properties.

Main Methods:

• Review of existing randomized clinical trials on lipid-lowering agents.
• Analysis of preclinical and clinical data on synthetic apolipoprotein mimetic peptides.
• Discussion of the mechanisms of action for apoA-I and apoE mimetics.

Main Results:

• Several drug classes effectively lower LDL cholesterol but only modestly increase HDL-C, with common side effects.
• Residual cardiovascular risk persists in some patients despite LDL-C reduction.
• Synthetic apoA-I and apoE mimetics show promise in positively impacting circulating lipoproteins and possess anti-inflammatory effects.

Conclusions:

• Synthetic apolipoprotein mimetic peptides represent a promising new therapeutic avenue for CAD.
• ApoA-I and apoE mimetics offer potential benefits beyond traditional lipid-lowering therapies.
• Emerging agents like AEM-28 are advancing through clinical trials, highlighting the progress in this field.